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Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) is an example of highly regulated
alternative splicing in which exons IIIb and IIIc are utilized in a mutually exclusive manner in different cell
types. The importance of this splicing choice is highlighted by studies which indicate that deregulation of the
FGF-R2 splicing is associated with progression of prostate cancer. Loss of expression of a IIIb exon-containing
isoform of FGF-R2 [FGF-R2 (IIIb)] accompanies the transition of a well-differentiated, androgen-dependent
rat prostate cancer cell line, DT3, to the more aggressive, androgen-independent AT3 cell line. We have used
transfection of rat FGF-R2 minigenes into DT3 and AT3 cancer cell lines to study the mechanisms that control
alternative splicing of rat FGF-R2. Our results support a model in which an important cis-acting element
located in the intron between these alternative exons mediates activation of splicing using the upstream IIIb
exon and repression of the downstream IIIc exon in DT3 cells. This element consists of 57 nucleotides (nt)
beginning 917 nt downstream of the IIIb exon. Analysis of mutants further demonstrates that an 18-nt “core
sequence” within this element is most crucial for its function. Based on our observations, we have termed this
sequence element ISAR (for intronic splicing activator and repressor), and we suggest that factors which bind
this sequence are required for maintenance of expression of the FGF-R2 (IIIb) isoform.
Alternative splicing, the process whereby a single pre-mRNA
is spliced differentially, represents a means by which gene ex-
pression can be modulated posttranscriptionally. An example
of alternative splicing in which tight regulation results in a very
defined cell type discrepancy in the differential expression of
isoforms occurs during the splicing of the second half of the
third immunoglobulin-like domain of the fibroblast growth fac-
tor receptor 2 (FGF-R2). Mutually exclusive splicing results in
a mRNA containing either the 148-nucleotide IIIb exon or the
145-nucleotide IIIc exon, a choice which is specific for a given
cell type (Fig. 1A). These mRNAs encode receptors with phys-
iologically relevant differences. FGF-R2 (IIIb) is the predom-
inant isoform expressed in epithelial cells and displays high
affinity for FGF-7 (or keratinocyte growth factor [KGF]) and
low affinity for FGF-2 (or basic FGF), whereas FGF-R2 (IIIc)
is expressed in certain cells of mesenchymal origin and exhibits
high affinity for FGF-2 but not for FGF-7 (7, 32–34, 46, 47, 53,
66). Thus, the specificity of this regulated splicing event is cru-
cial for the maintenance of proper pathways of cellular com-
munication and control of cell proliferation. Loss of appropri-
ate regulation of the splicing of FGF-R2 has been proposed to
be one step at which dysregulated growth pathways may lead to
progression of prostate cancer (10, 63). A well-differentiated,
androgen-dependent rat prostate cancer cell line, DT3 (or DT-
E), expresses the IIIb isoform of FGF-R2 exclusively, as do
normal rat prostatic epithelial cells. On the other hand, a poor-
ly differentiated, androgen-independent AT3 rat prostate can-
cer cell line expresses only the isoform containing IIIc. FGF-7,
secreted by prostatic stromal cells in response to androgens,
has been proposed to mediate controlled proliferation and
differentiation of epithelial cells through its interaction with
FGF-R2 (IIIb) (63, 64). Thus, it has been proposed that the
loss of appropriate regulation of FGF-R2 splicing may result in
the loss of a normal pathway of growth control in this model of
cancer progression (63).
It is implicit in models of alternative splicing that the pattern
of splicing is affected by cell-specific factors via interactions
with the constitutive splicing apparatus. Consensus sequences
located at the 59 splice site, the 39 splice site and associated
polypyrimidine tract, and the branch point are known to de-
termine splicing efficiency. The degree to which these signals
match the consensus sequences is in fact a determinant of the
ability of the constitutive splicing apparatus to recognize the
sequences and carry out the splicing reaction. The process of
splicing is performed by the spliceosome, which is comprised of
the small nuclear ribonucleoproteins U1, U2, U4/U6, and U5,
and associated splicing factors (reviewed in reference 50). A
mechanistic understanding of the means by which alternative
splicing can be regulated has been acquired largely through
study of the pathway of sex determination in Drosophila mela-
nogaster (reviewed in references 1, 31, 42, 43, and 45). Here,
examples of both activation and repression of specific splicing
pathways have been demonstrated to be affected by sex-specific
factors, which interact with components of the constitutive
splicing apparatus. Although these studies have provided ele-
gant models for regulated alternative splicing, there has not yet
been an example of alternative splicing in mammalian cells for
which the mechanism has been conclusively demonstrated or
for which cell type-specific splicing factors have been identi-
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fied. Several studies have shown that the pattern of splicing of
a pre-mRNA can be modulated in vitro and in vivo by changing
the levels of certain constitutive splicing factors known as SR
proteins, as well as that of heterogeneous nuclear ribonucleo-
protein particle A1 (hnRNP A1) (8, 18, 20, 42, 44). However,
it is not clear that differences in the levels of these factors will
suffice to explain the high degree of specificity observed in
numerous examples of mammalian alternative splicing. In ad-
dition to the strength of splice sites, exon size, intron size, and
the presence of specific exonic sequences have been shown to
have positive or negative effects upon splicing (5, 13–15, 17, 23,
30, 37, 55, 62). Recently, intronic sequences neighboring alter-
native exons have also been described which appear to be
targets of factors involved in regulating alternative splicing (2,
3, 9, 11, 14, 16, 22, 24, 26, 28, 29, 38, 40, 41, 48, 49, 52, 54, 58,
59, 67). Although several proteins have been shown to play
roles in interactions with these sequences, the precise means
through which these proteins mediate alternative splicing are
still unclear. A common observation in alternative splicing is
that the consensus splicing signals associated with one of the
splicing choices are “weak” matches to the consensus, and thus
a “default” splicing pathway, which may only require the co-
operation of members of the constitutive splicing pathways, is
regulated by a specific factor(s) that blocks the use of such a
default pathway and/or activates the weaker pathway. Exam-
ples have been well described for Drosophila, and it would
stand to reason that the existence of tissue- or developmental-
stage-specific factors which regulate alternative splicing will
eventually be demonstrated in mammalian systems.
The study of alternative splicing of human FGF-R2 has
demonstrated several exonic and intronic sequences which play
a role in the regulation of FGF-R2 splicing (14–16, 21). How-
ever, given the high degree of fidelity with which regulation is
maintained during splicing of the IIIb and IIIc exons, the
mechanism which would most easily explain the mutually ex-
clusive use of these exons and the roles of required cis ele-
ments has not been completely delineated. Using FGF-R2
minigenes in the DT3 and AT3 rat prostate cancer cell lines,
we have investigated sequences and mechanisms which regu-
late FGF-R2 splicing. Based on these studies, we have identi-
fied an intronic sequence between the IIIb and IIIc exons
which is necessary for appropriate regulation of FGF-R2 splic-
ing. This sequence has a high degree of homology with one of
the human sequences which has been shown by other investi-
gators to be involved in activation of splicing of the upstream
IIIb exon in a human cell line which uses the IIIb exon (16).
However, while we observed a similar, and in fact more dra-
matic, effect on activation of IIIb usage in our rat minigenes
and cells, we have also demonstrated that this sequence medi-
ates repression of use of the downstream IIIc exon in the same
cell line in which activation occurs. Therefore, we propose that
this sequence is required in order to achieve regulation
through coordinated activation of the weaker IIIb exon and
repression of the stronger IIIc exon in cells (DT3) which select
IIIb over IIIc.
MATERIALS AND METHODS
Plasmid construction. The pPIP11 adenoviral splicing construct is based on
the L1 and L2 exons and is similar to the previously described pPIP7A (36),
except that the sequence of the 39 exon between the PstI and HindIII sites has
been replaced by the sequence 59-CTGCAGGACAAACTCTTCGCGGTCTCT
ATGCATCCTCCGAACGGTAAGACCCTAAGCTT-39. The sequences of
pPIP11 were PCR amplified with primers PIP10-F (59-CCCGGGGGTACCGG
GCGAATTCGAATTCGAGCTCACTC-39) and PIP11-R (59-CCCGGGACTA
GTAAGCTTAGGCTCTTGGCGTT-39). The PCR product was digested with
EcoRI and SpeI and inserted into the EcoRI and XbaI sites of the eukaryotic
expression vector PCDNA3 (Invitrogen). All cloning was done by standard
methodologies. PCR amplification of genomic DNA from AT3 cells with the
FGF-R2-specific primer pairs Int 3BF2 (59-CCGGACTAGTCACTACCGTTC
TCCACCACT-39) and Int 3CR (59-CCGGCTCGAGGGTCGGAAATCATTC
GAAAC-39) and Intron 1F (59-CCGGACTAGTAAGCCCAAGGGGCCAGC
AGT-39) and Intron 3R (59-CCGGCTCGAGACGAAGAGCCAAGGGCGCC
T-39) yielded fragments FL and FS, respectively (Fig. 1B). These products were
digested with SpeI and XhoI and inserted into the XbaI and XhoI sites of the
pI-11 intron to yield pI-11-FL and pI-11-FS. Constructs derived from intron
deletions in pI-11-FS (see Fig. 4A) (for example, pI-11-FS-DBcl I/Nde I) were
obtained by first cloning the FS sequences into the SpeI and XhoI sites of
pBluescript (Stratagene) to generate pBlue-FS, since these enzymes cut within
PCDNA3 but not pBluescript. Deletions were performed by sequential digestion
of pBlue-FS with the indicated restriction endonucleases. The digested ends
were blunted with Pfu polymerase (Stratagene), and the resulting plasmids were
gel purified and religated with T4 DNA ligase. These plasmids were digested with
SpeI and XhoI, and the minigenes were cloned back into the XbaI and XhoI sites
of pI-11. Plasmids pI-11-IIIb-plus and pI-11-IIIb-minus were obtained with prim-
ers Int 3BF2 and Intron 2R2 (59-CCGGCTCGAGGGCTAGACATAGGAAT
GATT-39) and PCR amplification of pI-11-FS-DBcl I/Nde I and pI-11-FS-DBcl
I/Nsi I, respectively. After SpeI and XhoI digestion, the PCR products were
cloned into the XbaI and XhoI sites of pI-11. Plasmids pI-11-IIIc-plus and
pI-11-IIIc-minus were similarly obtained by PCR amplification with primers
Intron 2F (59-CCGGACTAGTCAACGTTTTTGTGTTTGTGT-39) and Int
3CR to amplify pI-11-FS-DBcl I/Nde I and pI-11-FS-DBcl I/Nsi I, respectively,
followed by digestion with SpeI and XhoI and insertion into the XbaI and XhoI
sites of pI-11. pI-11-FS-Not/Cla-ISAR resulted from PCR of pI-11-FS with
primers Nde/Not-F (59-CCGGCATATGGCGGCCGCCAAACAAATTCAAA
GAGAAC-39) and Nsi/Cla-R (59-CCGGATGCATATCGATGCGATTGAACA
CATGGAAAA-39), digestion of these products with NdeI and NsiI, and cloning
into the NdeI and NsiI sites in pBlue-FS. The minigene sequence was removed
with SpeI and XhoI and cloned into the XbaI and XhoI sites of pI-11 to generate
pI-11-FS-Not/Cla-ISAR. The ISAR mutant constructs pI-11-Not/Cla: Blue1,
FIG. 1. Structural organization of the FGF-R2 gene and demonstration of
IIIb and IIIc mutually exclusive splicing. (A) Organization of the FGF-R2 pro-
tein domains (top) and genomic gene arrangement of the region in which alter-
native splicing yields transcripts containing either the IIIb or IIIc exon and
encoding the second half of the third immunoglobulin (Ig)-like domain. TM,
transmembrane domain, TK, tyrosine kinase domains. The solid box represents
a highly acidic domain, and the thick line indicates the IIIb- or IIIc-encoded
portion of the protein. Shaded boxes represent exons, and solid lines represent
introns, with intron sizes indicated. U and D indicate the exons upstream and
downstream of these alternative exons, respectively. (B) Scale representation of
the exons (solid boxes) and introns (solid lines) with regions of high (at least
90%) rat-human intron sequence similarity (shaded boxes). Also shown are
regions FS and FL and their sizes. nt, nucleotide.
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SAR 59, SAR 39, SAR-20, Mut1, Mut2, Mut3, Blue2, Rep1, and Rep3 were
obtained by deleting ISAR from pI-11-FS-Not/Cla-ISAR with NotI and ClaI and
then inserting annealed oligonucleotides with complementary NotI and ClaI
sites, as represented by the following oligonucleotide pairs: Blue1-F, 59-GGAA
GCGACTCCCCGTCGTGTAGATAACTACGATACGGGAGGGCTTACCA
TCTGGCCCCAGTGAT-39; Blue1-R, 59-CGATCACTGGGGCCAGATGGT
AAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCGC-39;
SAR 59-F, 59-GGCCGCAAACAAATTCAAAGAGAACGGACTCTGTAT-39;
SAR 59-R, 59-CGATACAGAGTCCGTTCTCTTTGAATTTGTTTGGC-39;
SAR 39-F, 59-GGCCGCGGGCTGATTTTTCCATGTGTTCAATCGCAT-39;
SAR 39-R, 59-CGATGCGATTGAACACATGGAAAAATCAGCCCGC-39;
SAR-20-F, 59-GGCCGCCAAAGAGAACGGACTCTGTGGGCTGATTTTTC
CATGTAT-39; SAR-20-R, 59-CGATACATGGAAAAATCAGCCCACAGAG
TCCGTTCTCTTTGGC-39; Mut1-F, 59-GGCCGCCAAACTCTACGGACTCT
GTGGGCTGATTTTTCCATGTAT-39; Mut1-R, 59-CGATACATGGAAAAA
TCAGCCCACAGAGTCCGTAGAGTTTGGC-39; Mut2-F, 59-GGCCGCCAA
AGAGAACGGACTCTGTGGGCTGAAAGATCCATGTAT-39; Mut2-R, 59-
CGATACATGGATCTTTCAGCCCACAGAGTCCGTTCTCTTTGGC-39;
Mut3-F, 59-GGCCGCCAAAGAGAACGGACTCTGTGGGCTGATTTTTCA
CGCTAT-39; Mut3-R, 59-CGATAGCGTGAAAAATCAGCCCACAGAGTCC
GTTCTCTTTGGC-39; Blue2-F, 59-GGCCGCAAGTGGTGGCCTAACTACG
GCTACACTAGAAGGACACAT-39; Blue2-R, 59-CGATGTGTCCTTCTAGT
GTAGCCGTAGTTAGGCCACCACTTGC-39; Rep1-F, 59-GGCCGCGGGCT
GATTTTTCCATGTAT-39; Rep1-R, 59-CGATACATGGAAAAATCAGCCC
GC-39; Rep3-F, 59-GGCCGCGGGCTGATTTTTCCATGTGGGCTGATTTTT
CCATGTGGGCTGATTTTTCCATGTAT-39; and Rep3-R, 59-CGATACATG
GAAAAATCAGCCCACATGGAAAAATCAGCCCACATGGAAAAATCA
GCCCGC-39. All plasmid minigenes were prepared with plasmid maxi kits from
Qiagen. The identities of all minigenes were confirmed by automated DNA
sequencing with an ABI sequencer.
PCR amplification of DNA templates. PCR from DNA templates was per-
formed with 1 to 2 ng of plasmid DNA or 1 to 5 mg of genomic DNA and Taq
DNA polymerase (Boehringer Mannheim) according to the supplier’s recom-
mendations. Amplifications were performed with a Perkin-Elmer 2400 thermal
cycler. A typical cycle consisted of initial denaturation at 94°C for 4 min, followed
by 30 to 40 cycles of denaturation at 94°C for 30 s, annealing at 65°C for 1 min,
and extension at 72°C for 1 to 2 min. After completion of the final cycle, a final
extension was done at 72°C for an additional 7 min. For amplification of tem-
plates longer than 2 kb, we used TaqPlus (Stratagene) according to the manu-
facturer’s recommendations and cycles similar to those described above except
that extension times were generally 5 to 8 min.
Cell culture and transfections. AT3 and DT3 cells were maintained in Dul-
becco’s modified Eagle medium (Gibco) supplemented with 10% fetal bovine
serum (Hyclone). All transfections were performed in 35-mm-diameter wells
with 5 ml of Lipofectamine (Gibco) according to the supplier’s recommenda-
tions. Each well was seeded with 3 3 105 cells 16 to 24 h prior to transfection.
Pilot experiments with chloramphenicol acetyltransferase reporter plasmids
demonstrated that DT3 and AT3 cells were transfected with equivalent effi-
ciency. Transient transfections were done for 2 h with 50 ng to 2 mg of minigene
DNA, and RNA was harvested 24 h later. Stable transfections were performed
with 2 mg of minigene DNA, and after 24 to 48 h the cells were trypsinized and
reseeded in 75-cm2 flasks containing Geneticin (Gibco) at an active concentra-
tion of 400 mg/ml. Selection was performed until isolated colonies were obtained
and no cells remained from a control transfection with a plasmid lacking neo-
mycin resistance genes (usually 12 to 16 days). Pooled colonies were then har-
vested for RNA preparation.
RNA purification and RT-PCR analysis. Total cellular RNA was isolated from
transfected cells by the method of Chomczynski and Sacchi (12). Two micro-
grams of total RNA was heated to 100°C, chilled on ice, and reverse transcribed
in a reaction volume of 20 ml containing 50 mM Tris-HCl (pH 8.3), 75 mM KCl,
3 mM MgCl2, 10 mM dithiothreitol, 1 mM deoxynucleoside triphosphates, 100
ng of random hexamers, 2 U of RNasin (Promega), and 200 U of Moloney
murine leukemia virus reverse transcriptase (Gibco) at 37°C for 1 h. Samples
were then heated to 90°C for 5 min and then chilled on ice. Two microliters of
each reverse transcription (RT) reaction mixture was amplified in a 100-ml PCR
reaction mixture containing 50 mM KCl; 10 mM Tris-HCl (pH 8.8); 1.5 mM
MgCl2; 0.1% gelatin; 200 mM (each) dATP, dGTP, and TTP; 50 mM dCTP; 100
nM each primer; 10 mCi of [a-32P]dCTP; and 2.5 U of Taq DNA polymerase
(Boehringer Mannheim). The primers used were FGF-FB (59-CCCGGGTCTA
GATTTATAGTGATGCCCAGCCC-39) and FGF-RB (59-CCCGGGGAATTC
ACCACCATGCAGGCGATTAA-39) for analysis of the endogenous gene and
standard T7 and SP6 promoter primers for analysis of transfected minigenes.
Amplification conditions consisted of an initial denaturation at 94°C for 4 min
followed by 40 cycles of denaturation at 94°C for 30 s, annealing at 65°C for 30 s,
and extension at 72°C for 1 min and a final extension at 72°C for 7 min. In all
amplification reactions, a water control and a mock RT control were included,
which resulted in no PCR product in all experiments. PCR products were added
directly to restriction endonuclease digestions with either AvaI or HincII (New
England Biolabs). We always observed complete digestion when using this pro-
tocol. Aliquots representing equal amounts of each PCR reaction mixture with
undigested and digested PCR products were loaded directly on nondenaturing
5% polyacrylamide gels at 100 V for 3 to 4 h, followed by drying and exposure
to Amersham Hyperfilm-MP. Analysis was performed with a Molecular Dynam-
ics PhosphorImager. Because equal amounts of AvaI- and HincII-digested PCR
products were loaded onto each gel, quantification of cDNAs containing exon
IIIb or IIIc (UBD or UCD, respectively, where U and D are the 59 and 39 exons
of pI-11) was obtained by using the quantification of the band at 380 or 377 bp
which remained following HincII or AvaI digestion, respectively, as the numer-
ator. The denominator consisted of the sum of the bands remaining at 380 or 377
bp from both digests (UBD 1 UCD). When these results were also expressed
with the contribution of products with IIIb and IIIc skipped, the average value of
the 232-bp band was also used in the sum of the denominator (UBD 1 UCD 1
UD), corrected for molar equivalents. Quantification of experiments with mini-
genes with only one (IIIb or IIIc) internal exon was determined as the quanti-
fication of the 380- or 377-bp band divided by the sum of the same band and the
232-bp band, corrected for molar equivalents.
RESULTS
Nucleotide sequences of introns flanking alternative exons
IIIb and IIIc are highly conserved between rat and human
FGF-R2 genes. Because phylogenetic sequence comparisons
often help to identify sequences with important functions, we
chose to sequence the genomic DNA from the regions of both
rat and human FGF-R2 genes containing the alternative IIIb
and IIIc exons, the constitutive exons located upstream and
downstream of them, and the three introns between the exons.
As seen in Fig. 1 the intron sizes flanking the alternative exons
are roughly 1.1, 1.2, and 1.9 nucleotides in both rat and human
genomic sequences. Henceforth, these exons will be referred to
as intron 1, intron 2, and intron 3, respectively. We used the
University of Wisconsin Sequence Analysis Package GAP pro-
gram to align the rat and human sequences for direct sequence
comparison. As expected, the exon sequences were highly sim-
ilar and corresponded to previously reported cDNA sequences
for rat and human FGF-R2 (25, 46, 65). Interestingly, the
introns contained a number of regions with very high levels of
sequence similarity, and these regions were clustered around
the IIIb and IIIc exons, whereas the intron sequences adjacent
to the constitutive exons did not show appreciable levels of
similarity. We screened the rat sequence and highlighted all
intronic regions in which 90% of the nucleotides were identical
to the corresponding human sequence for a stretch of at least
20 consecutive nucleotides. These data are presented graphi-
cally in Fig. 1B. While we suspected that some of these regions
represented evolutionary vestiges, we also expected that regu-
latory sequences involved in mediating alternative splicing of
these exons, which have been conserved between rat and hu-
man genes, would also be likely to be represented by such
conserved sequences. Thus, this information was used to direct
the construction of a variety of minigenes, which will be de-
scribed below.
Minigenes pI-11-FL and pI-11-FS recapitulate the splicing
pattern of the endogenous gene in AT3 and DT3 cells. We used
an RT-PCR-based assay similar to one used by other research-
ers investigating the splicing of human FGF-R2 to assay for the
splicing pattern of exons IIIb and IIIc (14, 21). For analysis of
the endogenous FGF-R2 transcript, we performed RT-PCR
with primers (FGF-FB and FGF-RB) specific for the consti-
tutive exons located upstream of IIIb and downstream of IIIc,
as shown in Fig. 2A. These products were separately digested
with AvaI and HincII and analyzed by gel electrophoresis, as
shown in Fig. 2B. Because exon IIIb contains an AvaI site not
present in IIIc, and exon IIIc contains two HincII sites not
present in IIIb, we expected the inclusion of IIIb to result in a
367-bp product which is cut with AvaI but not HincII, and we
expected the inclusion of IIIc to result in a 364-bp product
which is cut only by HincII. As expected, DT3 cells produce an
FGF-R2 transcript which contains only exon IIIb and AT3 cells
consist entirely of transcripts containing IIIc, results which are
consistent with the original report describing alternative splic-
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ing of FGF-R2 in these cells (63). We also tested the validity of
this assay by performing the same assay with titrations in which
we mixed RNAs that contained only exon IIIb with RNAs
containing only exon IIIc, and we observed that the proportion
of each isoform seen by RT-PCR directly correlated with the
fraction of the same isoform in the mixture (data not shown).
Thus, mRNAs containing exon IIIb or IIIc were amplified with
equivalent efficiencies in this assay. Furthermore, sequencing
of these RT-PCR products verified that they were correctly
identified by this approach (data not shown).
In order to further characterize the cis elements required for
maintenance of the cell type-specific splicing patterns in DT3
and AT3 cells, we used PCR to amplify genomic regions FL
and FS from the rat FGF-R2 gene (Fig. 1B and 3A). These
sequences were cloned into the intron of splicing construct
pI-11, which is a two-exon, one-intron adenovirus-derived
splicing construct adapted for eukaryotic expression. As seen
in Fig. 1B and 3A, the resulting minigenes, pI-11-FL and pI-
11-FS, consisted of 4,378 and 1,804 nucleotides of genomic
FGF-R2 sequence, which represented exons IIIb and IIIc, the
entire intron 2 between IIIb and IIIc, and variable amounts of
introns 1 and 3. In the case of pI-11-FL, nearly all of introns 1
and 3 are included except intron sequences of the normal 59
splice site of the upstream exon-intron boundary and the polypy-
rimidine tract and the 39 splice site in the intron downstream of
exon IIIc. In constructing pI-11-FS we chose to limit the se-
quences from introns 1 and 3 to those regions closest to exons
IIIb and IIIc which contained greater-than-90% intron homol-
ogy, as described previously. It should be noted that in con-
structing these and all subsequent rat FGF-R2 minigenes we
substituted the adenoviral pPIP11 exons for the constitutive
exons normally used upstream and downstream of exons IIIb
and IIIc. We performed stable and transient transfections of
these minigenes in DT3 and AT3 cells with Lipofectamine and
harvested RNA 24 h later for transient transfections or after
colony formation 12 to 16 days later for stable transfection
analysis. We then performed labeled RT-PCR with primers
(the T7 and SP6 promoter primers) specific for PCDNA3. As
we will detail later, results from transient transfections were
highly dependent on the amount of minigene DNA trans-
fected, and thus we predominantly used stable transfections
due to their easier reproducibility. Initial experiments with
pI-11 in both DT3 and AT3 cells showed that the adenoviral
strong consensus splice sites directed highly efficient splicing in
both cell lines, with the pre-mRNA transcript being spliced
essentially to completion (Fig. 3B). In order to analyze the
splicing products of pI-11-FL and pI-11-FS, we digested the
RT-PCR products with AvaI and HincII and performed poly-
acrylamide gel electrophoresis. When stable transfections with
pI-11-FL and pI-11-FS were analyzed as shown in Fig. 3C and
D, the primary product was 380 or 377 bp, and this product
contained almost exclusively exon IIIb in DT3 cells and IIIc in
AT3 cells. In addition, we observed a minor 525-bp band,
which corresponded to a product which contained both IIIb
and IIIc, as well as a 232-bp product, which results when the
pI-11 exons are directly spliced together. The origins of the
products obtained when these products are digested with AvaI
and HincII are shown in Fig. 3E. Of note, digestion of the
525-bp product, which contains both exons IIIb and IIIc, re-
sults in a band at 394 bp, just above the location of the pre-
dominant product of 380 bp, which is nearly completely di-
gested by AvaI (Fig. 3C and D, lanes 2). Thus, this product is
not to be confused with undigested 380-bp products. Although
the splicing product containing both exons was seen reproduc-
ibly in all experiments, it was a minor product on a molar basis,
and thus, for simplicity we did not include it in our further
analysis. We did note in these and subsequent experiments that
the amount of product seen in which both IIIb and IIIc were
skipped and the pI-11 exons were directly spliced was slightly
higher in DT3 cells than in AT3 cells, which may in part reflect
the fact that the IIIb exon contains a weaker polypyrimidine
tract than that associated with exon IIIc. In order to evaluate
the efficiency of usage of IIIb and IIIc in our experiments, we
used PhosphorImager analysis to quantify the levels of prod-
ucts containing IIIb (in DT3 cells) or IIIc (in AT3 cells).
Because loss of a pathway selecting either IIIb or IIIc (but not
both) has two consequences (i.e., a switch to use the other exon
or to skip both and directly splice the pI-11 exons), we quan-
tified our results both including and excluding the contribution
of this skipping pathway. These experiments with stable trans-
fections demonstrated that we could reproduce the endoge-
nous gene’s pattern of regulated splicing of the IIIb and IIIc
exons with a high degree of precision. We were also able to
demonstrate that the sequences in the exons normally located
upstream of exon IIIb and downstream of IIIc, as well as most
of the sequences of introns 1 and 3, are dispensable for main-
tenance of regulated splicing of these exons of FGF-R2.
Deletion of nucleotide sequences between the NdeI and NsiI
sites located in intron 2 causes loss of splicing regulation. To
further characterize intron sequences required for splicing reg-
ulation, we constructed a series of deletions in intron 2 of
pI-11-FS. The deletions tested are shown in Fig. 4A along with
a map in which the regions of high rat-human homology are
superimposed on the locations of the restriction enzymes used
to create these deletions. The resulting minigenes were stably
transfected into DT3 and AT3 cells. The results of the entire
series of deletions are summarized in Fig. 4A, and selected gels
FIG. 2. Splicing of the endogenous gene transcript in DT3 and AT3 cells. (A)
Map illustrating PCR products containing exon IIIb or IIIc amplified with prim-
ers FGF-FB and FGF-RB and sizes (in nucleotides) of fragments which result
from AvaI or HincII digestion. U, upstream exon; D, downstream exon. (B) Gel
showing the RT-PCR products following digestion with AvaI and HincII. DT3
cells express only products containing IIIb, and AT3 cells express products
containing IIIc. U, uncut products; A, AvaI-digested products; H, HincII-di-
gested products; M, pBR322/Msp I DNA size markers.
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FIG. 3. Rat FGF-R2 minigenes transfected into DT3 and AT3 cells repro-
duce the splicing pattern of the endogenous gene. (A) Representation of the
two-exon, one-intron splicing construct pI-11 and insertion of FGF-R2 genomic
sequences FL and FS (which were generated with the primer sets indicated at
bottom) to create minigenes pI-11-FL and pI-11-FS, respectively. CMV indicates
the efficient immediate early CMV promoter, and pA indicates the bovine
growth hormone polyadenylation sequence. The XbaI and XhoI sites used for
cloning and the T7 and SP6 vector-specific primers are also indicated. U, the 59
exon of pI-11; D, the 39 exon of pI-11. (B) pI-11 pre-mRNA is spliced almost
completely and with equal efficiency in DT3 and AT3 cells, indicating no differ-
ences in the abilities of these cells to splice the exons. RT-PCR products for this
and subsequent minigenes were obtained with the T7 and SP6 promoter primers.
(C and D) Minigenes pI-11-FL and pI-11-FS reproduce the endogenous gene
splicing pattern. The major PCR product containing either IIIb (3B or B) or IIIc
(3C or C) is 380 or 377 bp, respectively. Products containing exons U, IIIb, IIIc,
and D are indicated to the right. The sizes of products of AvaI and HincII
digestion are also indicated. Quantification was performed to yield values for the
fraction of the expected IIIb (in DT3) or IIIc (in AT3) exon as a fraction of
products containing IIIb and IIIc and also as a fraction of products skipping IIIb
and IIIc (see Results and Materials and Methods). (E) Representation of the
origins (in nucleotides) of the products obtained when UBD, UCD, and UBCD
products are cut with AvaI and HincII. Sizes are indicated in base pairs. Lanes
are labeled as in Fig. 2.
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representing the most informative deletions are shown in Fig.
4B and C. It should first be noted that a deletion from the BclI
site at position 302 to the NdeI site at 915 which removed more
than half of intron 2 did not appreciably affect appropriate
splicing regulation in either DT3 or AT3 cells; DT3 cells used
IIIb and AT3 cells used IIIc (Fig. 4B and C). However, any
deletion which included the sequences between the NdeI and
NsiI sites at positions 915 and 978 resulted in a dramatic loss of
exon IIIb usage by DT3 cells. This loss of regulation in DT3
cells was reflected by increased usage of the IIIc exon as well
as by increased skipping of both exons, as seen in Fig. 4B. In
addition, we noted that a deletion from NsiI to StuI also caused
a decrease in IIIb usage, but not nearly as much as a much
smaller deletion from the NdeI to NsiI sites. As demonstrated
in Fig. 4C, when any of these minigenes with deletions were
stably transfected into AT3 cells, appropriate use of the IIIc
exon was not affected nor was any increased level of skipping
observed. Because nearly identical results were obtained in
AT3 cells with all manipulations of intron 2 sequences, we will
subsequently mainly show results obtained in DT3 cells.
Sequences between the NdeI and NsiI sites mediate regula-
tion in DT3 cells by activating use of the upstream IIIb exon as
well as by repressing use of the downstream IIIc exon. The
results obtained with deletions in intron 2 suggested that the
requirements for exon IIIc inclusion in AT3 cells are less
stringent than those for IIIb inclusion in DT3 cells. In fact, with
FIG. 4. Deletions which result in loss of sequences between the NdeI and NsiI sites in intron 2 result in loss of regulation in DT3 cells. (A) The IIIb and IIIc exons
(solid boxes) and the intron (intron 2) between them (solid line) are shown. Also indicated are the restriction enzymes used to generate these deletions and the regions
of high rat-human sequence homology (shaded boxes). The locations of these restriction sites are represented as the position (in nucleotides) from the start of the intron
and are measured to the center position of each recognition sequence. The minigenes tested consisted of deletions (hatched boxes) from the parent construct, pI-11-FS,
and the results of these deletions in DT3 cells are summarized. Delta, construct in which the sequence between the indicated restriction enzymes was deleted from
pI-11-FS; plus, deletion constructs which still demonstrated .80% IIIb inclusion in DT3 cells; minus, deletion constructs with #55% IIIb inclusion in DT3 cells. (B)
Results of the most representative intron 2 deletions in DT3 cells. Deletion of over half of the intron from BclI to NdeI did not affect regulation, whereas deletions
spanning NdeI to NsiI caused loss of regulation. A deletion of NsiI-to-StuI sequences also caused some loss of regulation, but less than a NdeI-to-NsiI deletion. (C)
The same deletions had no effect upon splicing in AT3 cells. Efficient IIIc usage was seen in these deletions, as well as all deletions summarized in panel A.
Abbreviations are defined in the legends to Fig. 2 and 3.
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our sets of minigenes we did not observe any intronic se-
quences outside of the conserved splice junctions or polypy-
rimidine tract which impeded splicing of IIIc in AT3 cells. As
we have discussed, this is not surprising given the stronger
polypyrimidine tract associated with the IIIc exon compared to
that of IIIb. Therefore, while we cannot completely rule out
the possibility that there are other untested intron sequences
or exon IIIc sequences which interact with AT3 cell-specific
factors to mediate IIIc inclusion in these cells, we hypothesized
that IIIc exon inclusion is a default splicing pathway which may
only require the cooperation of factors involved in the consti-
tutive splicing process. Thus, regulation may be achieved by
proteins in DT3 cells which are able to switch the splicing
pattern from exon IIIb to IIIc. Consistent with this view are the
observations that several of our deletions caused not only skip-
ping of both exons but also a switch towards some IIIc inclu-
sion. Therefore, if FGF-R2 mutually exclusive alternative
splicing is predominantly regulated only in DT3 cells, the se-
quences which are involved in this regulation could be acting
by activating IIIb splicing or repressing IIIc splicing or by
performing both of these functions. To investigate these alter-
natives, we constructed a series of minigenes in which we
inserted either IIIb or IIIc (but not both) into pI-11 and we
used our previous deletions in such a manner that IIIb was
inserted either with (pI-11-IIIb-plus) or without (pI-11-IIIb-
minus) the NdeI-to-NsiI sequences located downstream and
IIIc was inserted with (pI-11-IIIc-plus) or without (pI-11-IIIc-
minus) these same sequences upstream (Fig. 5A). Because
these minigenes only offered a choice of including an internal
exon or skipping, we quantified use of the internal IIIb or IIIc
exon versus that of the skipped product. As shown in Fig. 5B,
when these minigenes were transfected into AT3 cells, the IIIc
exon was included highly efficiently, and this inclusion was not
affected by the presence of the NdeI-to-NsiI sequences located
upstream. In addition, AT3 cells did not include exon IIIb
efficiently and this effect was essentially unchanged whether or
not these sequences were located downstream. In DT3 cells,
on the other hand, IIIb inclusion was seen to occur with fairly
high efficiency, but this inclusion was largely dependent on the
presence of the NdeI-to-NsiI sequence located downstream;
when this sequence was deleted, IIIb inclusion was dramati-
cally reduced from 68 to only 13%. In addition, we noted that
when the NdeI-to-NsiI sequences were present upstream of
IIIc, DT3 cells rarely included IIIc, but when these sequences
were deleted, the proportion of IIIc included approximately
tripled, from 11 to 35%. These data were consistent with a
model in which regulation of FGF-R2 alternative splicing in
DT3 cells is achieved by the interaction of a cell-specific factor
or complex of factors with intronic sequences in intron 2 and
the coordinated activation of exon IIIb splicing and repression
of the stronger IIIc exon. The fact that the sequences between
NdeI and NsiI were necessary for both of these effects to occur
prompted us to call this sequence ISAR (for intronic splicing
activator and repressor), and it suggests that this element is
required for the formation of a regulatory complex which acts
in DT3 cells to force the use of IIIb instead of IIIc.
A core sequence of 18 nucleotides within the ISAR sequence
mediates splicing regulation in DT3 cells. In order to further
characterize the sequences in this NdeI-to-NsiI ISAR element
which are required for regulation, we prepared a series of
deletion mutants to see which regions appeared most crucial.
In order to facilitate easier manipulation of the ISAR se-
quence, we created a new minigene, pI-11-FS/Not/Cla-ISAR,
in which we used PCR to engineer a NotI site directly 39 of the
NdeI site and also placed a ClaI site directly 59 of the NsiI site
in intron 2. Thus, this minigene was identical to pI-11-FS
except that the NdeI and NsiI restriction sequences were sep-
arated from the 57 nucleotides normally located between them
by the NotI and ClaI sites, respectively. We stably transfected
pI-11-FS/Not/Cla-ISAR into DT3 and AT3 cells and observed
FIG. 5. Sequences contained between the NdeI and NsiI sites of intron 2 normally function to activate upstream IIIb splicing and repress downstream IIIc splicing.
(A) Method used to generate minigene constructs containing either the IIIb or IIIc exon with NdeI-to-NsiI sequences (crosshatched boxes) present or deleted. All
constructs had sequences BclI to NdeI, which were previously shown to be dispensable for regulation, deleted. The primers used to generate these regions in relation
to the sequences of pI-11-FS are shown. The hatched box represents polylinker sequences present in PCDNA 3. (B) Transfection of the minigenes into DT3 and AT3
cells reveals that AT3 cells use exon IIIc highly efficiently and do not use exon IIIb efficiently regardless of the presence of NdeI-to-NsiI sequences. DT3 cells use exon
IIIb efficiently only when these NdeI-to-NsiI sequences are present downstream. DT3 cells do not use exon IIIc efficiently, but when these sequences are deleted, IIIc
usage triples. Quantifications were performed as described in Materials and Methods. Abbreviations are defined in the legend to Fig. 3.
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essentially no differences between the splicing patterns with
this construct and that of pI-11-FS; splicing regulation was
preserved (Fig. 3D, lanes 1 to 3, and 6B, lanes 1 to 3). We then
replaced the 57-nucleotide ISAR element with sequences con-
sisting of parts of the ISAR sequence or containing mutations
within the ISAR sequence (Fig. 6A). In addition we also re-
placed the ISAR element with random sequences chosen from
pBluescript as controls, to verify that the effects of our dele-
tions were a result of loss of this sequence and not due to
changes in the size of the intron and thus possibly in the
proximity of other cis-acting elements.
We first tested minigenes in which we replaced the full ISAR
sequence with only the most 59 29 nucleotides (SAR 59), the 39
28 nucleotides (SAR 39), or the central 37 nucleotides (SAR-
20) as outlined in Fig. 6A. We also introduced a 57-nucleotide
sequence from pBluescript (Blue1) as a control for the size of
ISAR. When these constructs were stably transfected into AT3
cells, we again observed highly efficient, nearly exclusive use of
exon IIIc (data not shown). In DT3 cells we observed a dra-
matic reduction in IIIb inclusion with the control Blue1 se-
quences as well as with SAR 59 (Fig. 6B). SAR 39 and SAR-20,
however, nearly restored splicing regulation, although IIIb in-
clusion with SAR 39 was slightly less efficient than with SAR-
20. Because SAR-20 restored splicing regulation almost to the
levels seen with full-length ISAR, we also tested several mu-
tations (Mut1, Mut2, and Mut3) within this sequence in which
we mutated 4 consecutive nucleotides within SAR-20 by re-
placing purines with pyrimidines or vice versa. In addition,
because both SAR-20 and SAR 39 nearly restored regulation
we tested the effect of the 18 nucleotides these sequences
shared (Rep1 [Fig. 6A]) as well as three repeats of this se-
quence (Rep3). We also included a second negative control
from a different part of pBluescript (Blue2), which was 37
nucleotides long in order to correspond to the size of SAR-20.
We noted loss of regulation in DT3 cells when either of the
Bluescript sequences was used, as well as when either Mut2 or
Mut3, which were located within the 18 nucleotides which
appeared to be most critical, were used (Fig. 6C). However,
Mut1, Rep1, and Rep3 sequences were all capable of at least
partially restoring splicing regulation (Fig. 6C and D). In fact,
FIG. 6. A critical 18-nucleotide sequence within the 57-nucleotide ISAR sequence between NdeI and NsiI nearly restores splicing regulation in DT3 cells. (A) The
57-nucleotide ISAR sequence is indicated at the top, and deletions and mutants of this sequence are shown below, as are control pBluescript sequences. The
18-nucleotide core sequence (Rep1) is boxed, and mutant sequences are underlined and in boldface. All sequences were tested by deleting ISAR sequences from
pI-11-FS/Not/Cla-ISAR and inserting the indicated sequences. (B) SAR-20 and SAR 39 sequences restore regulation, whereas SAR 59 does not. (C) Mutations in the
18-nucleotide sequence shared by SAR-20 and SAR 39 (Mut2 and Mut3) cause loss of regulation, whereas a mutation outside this region (Mut1) preserves regulation.
(D) One or three copies of the 18-nucleotide core sequence restore splicing regulation, with three repeats of the sequence being slightly more efficient than one repeat.
Abbreviations are defined in the legends to Fig. 2 and 3.
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three repeats of this 18-nucleotide region appeared to be
slightly more efficient than one repeat, although not better
than full-length ISAR (Fig. 6D). Thus, this 18-nucleotide re-
gion contained most of the sequences required for regulation
by the ISAR element, although given the slightly decreased
level of restoration of regulation by SAR 39 and Rep1 com-
pared to that by ISAR or SAR-20, other sequences within
ISAR may have minor contributing roles.
Regulated splicing in DT3 cells is dependent on a titratable
factor or factors. In our initial experiment using the FGF-R2
minigenes pI-11-FS and pI-11-FL in transient transfections
with 2 mg of plasmid DNA, we noted that AT3 cells utilized the
IIIc exon exclusively, as we observed in stable transfections;
however, the DT3 cells also predominantly used the IIIc exon,
with only a minor component of IIIb usage. Because transfec-
tion with Lipofectamine is highly efficient, we hypothesized
that splicing regulation was not being seen in these experi-
ments because the amount of RNA produced in the transient
transfections may have been overwhelming the regulatory fac-
tors present in DT3 cells. Therefore, using pI-11-FS, we ti-
trated the amount of plasmid DNA used in these transfections
of DT3 cells as shown in Fig. 7. It can be seen that when we
used amounts of DNA in the range of 50 to 100 ng we were
able to achieve nearly (but not quite) the same degree of IIIb
inclusion as that obtained with stable transfections and the
endogenous gene. As the amount of DNA used in the trans-
fection is increased, a stepwise reduction in IIIb inclusion is
seen. In fact a similar effect was previously observed with
human FGF-R2 minigenes, and in that case, curiously, the
effect was abrogated through maintenance of an open reading
frame in the minigene (21). Transient transfection of a mini-
gene which does not contain ISAR (pI-11-FS D Nde I/Nsi I)
resulted in nearly exclusive use of the IIIc exon even with only
50 ng of DNA (data not shown). Thus, ISAR is likewise re-
quired for maintenance of splicing regulation in transient
transfections. However, this regulation is compromised when
larger amounts of a minigene are transfected, most likely due
to overtitration of a factor or factors required for IIIb inclu-
sion.
The core sequences of ISAR are highly homologous with a
similar sequence in human FGF-R2 shown to mediate IIIb
activation in human cells which express FGF-R2 (IIIb). Re-
cently Del Gatto and colleagues (16) described several se-
quences, located in the same region of the human gene be-
tween exons IIIb and IIIc as ISAR occupies in the rat gene,
which were required for upstream IIIb activation, although the
effects of these sequences on IIIc repression were not charac-
terized. In addition, several other intronic sequences, as well as
exon sequences in IIIb, have also been shown to be required
for proper splicing regulation (14, 15). These investigators
proposed that a sequence element similar to the 18-nucleotide
core sequence in our rat ISAR could form an RNA secondary
structure with another important intronic sequence, IAS2, ap-
proximately 800 nucleotides upstream from this sequence. It
was further proposed that this secondary structure was a nec-
essary element involved in exon IIIb activation. Interestingly,
as shown in Fig. 8, the rat sequences corresponding to both of
these elements are highly similar to the human sequences.
While we did not directly test the validity of this model with rat
FGF-R2 minigenes, it is interesting to note that in all of the rat
minigenes tested here, including those with only one of the two
exons, the corresponding upstream sequence was always in-
cluded. Thus, possible synergistic effects of these separate se-
quences on FGF-R2 splicing regulation, whether or not they
function via formation of a secondary structure, may be in-
volved in the repression of IIIc as well as in IIIb activation.
DISCUSSION
We have described the identification of an important cis-
acting element in rat FGF-R2 which is required for proper
splicing regulation of the mutually exclusive IIIb and IIIc ex-
ons. Because this 57-nucleotide element was shown to cause
both activation of the upstream IIIb exon and repression of the
downstream IIIc exon, effects exclusive to DT3 cells, we have
termed this sequence ISAR. Within this sequence we have
further identified 18 nucleotides which appear to be the most
critical region for the regulation of splicing, and we have shown
FIG. 7. DT3 cells contain a titratable factor or factors required for appro-
priate splicing regulation which can be overcome in transient transfections.
Transient transfection of DT3 cells with increasing numbers of pI-11-FS mini-
genes resulted in stepwise loss of IIIb inclusion and increased IIIc inclusion,
suggesting that a factor or factors required for regulation (i.e., IIIb inclusion
and/or IIIc exclusion) is overwhelmed when large numbers of these minigenes
are transfected. Abbreviations are defined in the legends to Fig. 2 and 3.
FIG. 8. Intron sequences important for regulation of rat and human FGF-R2 splicing are highly similar. (A) Rat intron sequences corresponding to a previously
reported 21-nucleotide human sequence, IAS2 (see Results), which also mediates IIIb activation, contain only 1 nucleotide difference. (B) The 57-nucleotide rat ISAR
sequence is highly similar to human sequences in this same region, including the 18 nucleotides shown to be most important for regulation (boxed sequences).
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that this sequence is highly similar to a similarly situated se-
quence in the human FGF-R2 gene which has been shown to
mediate IIIb activation. Based on our data, we suggest a model
of regulation in this system, which our data support in several
ways, and furthermore show that this ISAR sequence is a
necessary, although perhaps not sufficient, element involved in
this model. We suggest that in AT3 cells splicing of the IIIc
exon occurs by a default pathway in which members of the
constitutive splicing apparatus are capable of recognizing the
splice sites associated with this exon and splicing occurs with
high efficiency. DT3 cells, on the other hand, are a regulated
cell line with respect to IIIb exon usage, requiring a factor(s)
not present in AT3 cells or not present at a level sufficient to
mediate IIIb inclusion and IIIc exclusion. We further propose
that this DT3-specific regulation mediates both activation of
splicing to the upstream, weak IIIb exon and repression of
splicing to the downstream, strong IIIc exon (Fig. 9). Several
lines of evidence support this model. First, the polypyrimidine
tract associated with the IIIc exon is a significantly stronger
match to the high-pyrimidine-content consensus sequence than
that of the IIIb exon. Thus, in AT3 cells, the IIIb exon is
recognized poorly by constitutive splicing factors in the ab-
sence of specialized factors. Second, although we cannot rule
out regulation in AT3 cells by untested sequences, we per-
formed a large series of intron deletions and never observed
any decrease in the efficiency of IIIc usage in AT3 cells. Third,
IIIc inclusion approaches 100% even when our minigenes are
transfected at very high levels in these cells, whereas in DT3
cells IIIc inclusion increases proportionally as higher numbers
of minigenes are transfected. These observations suggest the
presence of a factor or factors in DT3 cells which are needed
to achieve cell-appropriate IIIb-exclusive splicing. The fact that
such a factor(s) can be titrated is further evidence for the
presence of a specific protein(s) in DT3 cells which is distinct
from factors normally associated with constitutive splicing
processes and which regulates specific splicing events. The
specificity of such a factor(s) is further supported by the dem-
onstration of a cis element, ISAR, which is required for ap-
propriate exon IIIb splicing in DT3 cells.
Is ISAR alone capable of mediating the observed effects on
FGF-R2 splicing? It appears that there are several cis elements
involved in mediating appropriate regulation of FGF-R2 splic-
ing. At present it is unclear whether these sequences are rec-
ognized in a coordinated manner or if each is recognized in-
dependently by both cell-specific and non-cell-specific factors
which exert additive effects upon splicing. Investigation of al-
ternative splicing in a number of systems has been complicated
by the frequent observation that multiple intronic and exonic
cis elements are involved in mediating the splicing efficiencies
of alternative exons (2, 11, 14, 16, 28, 29, 57). An interesting
observation has been that regulated exons often contain pu-
rine-rich enhancer sequences, which have been shown to en-
hance the activation of exons that contain them, effects which
have been shown to involve the SR family of splicing factors
(17, 30, 37, 55, 61, 62). However, so far these “exonic enhanc-
ers” have not been shown to exert tissue-specific effects but
rather appear to influence the efficacy with which the exons
containing them are spliced. Similarly, examples of repression
by exon sequences as well as of both activation and repression
of splicing by intronic sequences have also been described.
Thus, in addition to the strength of splice site sequences, it may
be that the relative strength of a given splicing pattern can be
influenced by a number of cis elements whose effects may be
general and not specific for a given cell type; rather they may
set a balance between splicing choices, which can then be
manipulated by cell-specific factors.
The challenge, then, is to identify regulatory sequences
which function as the “switch” by binding a factor(s) which can
exert cell-specific effects upon splicing. In the case of FGF-R2,
several cis elements have been demonstrated to modulate
the splicing efficiency of the IIIb exon (14–16). These ele-
ments include a specific sequence within the IIIb exon which
represses its use; a polypyrimidine-rich sequence just down-
stream of exon IIIb (IAS1); and another sequence element,
IAS2, just downstream from IAS1, as well as the ISAR se-
quence reported here, which is similar to a human sequence,
IAS3, just recently described. It is worth noting that each of
these sequences is highly homologous between rats and hu-
FIG. 9. Depiction of a model which can account for our results and the high fidelity of FGF-R2 splicing. AT3 cells use a default splicing pathway and choose the
IIIc exon because of its stronger polypyrimidine tract (ppt); they splice IIIb inefficiently due to its weaker polypyrimidine tract. DT3 cells require a regulatory factor(s)
which can activate (1) the weaker IIIb exon and at the same time repress (2) use of the IIIc exon. The ISAR element (indicated by a hatched box) is shown binding
a factor or complex of factors (large shaded oval) which mediates both of these effects. The previously demonstrated contributions of other cis elements and associated
factors (smaller shaded ovals) to IIIb activation are also shown, as well as the suggestion of possible cooperative interaction between proteins bound at several locations
within the intron. Abbreviations are defined in the legend to Fig. 3.
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mans. Because we noted that deletion of sequences down-
stream of ISAR also causes some loss of regulation, it is likely
that a cis element is present there as well. In the case of the
first three elements, the original investigators, using various
combinations of these sequences, showed that their effects
upon splicing were not necessarily cell type specific, as each
could exert these effects in both HeLa cells (which use IIIc)
and SVK14 cells (which use IIIb), depending upon the context
in which each was tested (14). Thus, one possibility is that some
of these elements in both exons and introns exert general
effects upon splicing efficiency. The fact that ISAR is required
for both IIIb activation and IIIc repression suggests that this
sequence may be more likely to be involved in the binding of
cell-specific factors, although it may require additional se-
quences (with their associated factors) in order to exert tight
regulation in this system. Del Gatto and colleagues (16) re-
cently proposed that a human sequence with high similarity to
ISAR, IAS3, may form a secondary structure with IAS2 which
is a prerequisite for its function in the activation of IIIb splic-
ing, although a role for IAS3 in IIIc repression was not de-
scribed. As noted previously, sequences in the same region of
the rat sequence as IAS2 occupies in the human sequence are
also highly similar to their human homologs and would be
predicted to form a similar secondary structure with ISAR.
When we tested for the effects of ISAR on activation of IIIb
and repression of IIIc we serendipitously included these se-
quences, and therefore we cannot rule out the possibility that
they are required in a cooperative role in order for these effects
to be exerted. Interestingly, however, even when only the effect
of either IAS2 or IAS3 on the activation of human IIIb splicing
was studied, the effect of deleting these sequences was less
pronounced than that which we achieved with deletion of the
rat ISAR, and complete loss of regulation in the experiments
of Del Gatto et al. required mutation of IAS1. Studying the rat
gene, however, we have demonstrated in this paper that we can
obtain nearly complete loss of regulation by mutating ISAR
alone, without altering a sequence homologous to IAS1. Thus,
it is possible that there are some key differences in the degree
to which these various cis elements function to mediate alter-
native splicing of rat and human FGF-R2.
Clarification of the mechanism by which ISAR and other
intronic sequences change the pattern of splicing will require
further biochemical study, but several other systems have pro-
vided clues as to how intron sequences can affect splicing.
Intron sequences which are capable of activating splicing have
been identified in gene transcripts from c-src (4, 48, 49), fi-
bronectin (28, 29), calcitonin/CGRP (41), cardiac troponin T
(9, 57), and b-tropomyosin (59). In the case of c-src, an intronic
activating sequence has been shown to promote inclusion of an
upstream neural-cell-specific exon via formation of a multipro-
tein complex containing heterogeneous nuclear ribonucleo-
protein particle F (hnRNP F) and a novel protein, KH-type
splicing regulatory protein (KSRP), although neither of these
proteins is neural cell specific (48, 49). It has been proposed
that one function of these activators, which are mostly located
in the intron downstream of a regulated exon, is to promote
binding of U1 to the upstream 59 splice site (4, 49), which could
then promote U2AF binding to the upstream polypyrimidine
through cross-exon interactions which mediate exon definition
(27, 56). Repression mediated by intronic sequences has also
been described in several genes; examples include c-src (11)
and the genes encoding a- and b-tropomyosin (22, 39, 52, 54,
58) and the g2 subunit of the GABA receptor (2). In these
cases an emerging theme has been the participation of polypy-
rimidine tract binding protein (PTB) (6, 19), which may block
U2 binding to the branch point (39) and possibly interfere with
U2AF binding as well (58), although given the ubiquitous
expression of PTB it is still unclear how the specificity of
repression can be achieved by PTB alone.
Mutually exclusive models of alternative splicing contain an
additional level of complexity. In the case of mutually exclusive
exons 2 and 3 of the a-tropomyosin gene, the presence of a
branch point only 41 nucleotides downstream of exon 2 pre-
vents inclusion of both exons, and exon 3 is the default exon in
unregulated cells (22, 51, 60). When exon 3 is repressed, exon
2 usage can be achieved, even in the absence of specific factors
promoting its use. In the chicken tropomyosin gene, a 33-
nucleotide sequence, located in the intron between mutually
exclusive exons 6A and 6B, was suggested to function in a
manner similar to that which we propose for ISAR, as its
deletion led to both loss of activation of the upstream 6A exon
and derepression of the downstream 6B exon (3). However,
this conclusion was weakened by the observation that replacing
this sequence with its complementary sequence showed a sim-
ilar effect, and unlike ISAR, any repositioning of this element
abrogated the effect. Thus, our data are perhaps the most
definitive to date which demonstrate a specific effect of a cis-
acting intronic element which is required to facilitate activation
of an upstream exon while also repressing a downstream exon.
The ability of one cis-acting sequence to mediate both activa-
tion and repression is somewhat (although not directly) anal-
ogous to the experiments of Kanopka et al. (35), in which an
exonic sequence which normally activates splicing at the up-
stream polypyrimidine tract causes repression of splicing when
placed in the intron upstream of the same polypyrimidine tract.
Although our ISAR sequence is positioned only in an intronic
location, it may be that factors which bind this sequence are
involved in mediating the opposite effects on splicing of an
upstream versus a downstream exon. Identification of proteins
which bind to ISAR and possibly other cis elements in the
FGF-R2 gene transcript will hopefully yield a clearer picture of
the process through which these multiple elements are used to
modulate the activity of the constitutive splicing apparatus to
yield distinct mRNAs in different cell types.
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